Dupixent Dosing Frequency
Dupixent (dupilumab) is most commonly dosed every 2 weeks (Q2W) for adults and adolescents, though dosing frequency varies significantly by indication, age, and weight, ranging from weekly to every 4 weeks. 1
Dosing by Indication
Atopic Dermatitis
Adults:
- Initial loading dose: 600 mg (two 300 mg injections)
- Maintenance: 300 mg every 2 weeks (Q2W) 1
Pediatric patients (6-17 years):
- Weight-based dosing with variable intervals 1:
- 15 to <30 kg: 300 mg every 4 weeks (Q4W) after 600 mg loading dose
- 30 to <60 kg: 200 mg every 2 weeks (Q2W) after 400 mg loading dose
- ≥60 kg: 300 mg every 2 weeks (Q2W) after 600 mg loading dose
Young children (6 months to 5 years):
- No loading dose in this age group 1
- 5 to <15 kg: 200 mg every 4 weeks (Q4W)
- 15 to <30 kg: 300 mg every 4 weeks (Q4W)
Asthma
Adults and adolescents (≥12 years):
- Standard: 200 mg or 300 mg every 2 weeks (Q2W) after loading dose 1
- For oral corticosteroid-dependent asthma or comorbid moderate-to-severe AD: 300 mg every 2 weeks after 600 mg loading dose
Children (6-11 years):
- 15 to <30 kg: 300 mg every 4 weeks (Q4W), no loading dose
- ≥30 kg: 200 mg every 2 weeks (Q2W), no loading dose 1
Other Indications
- Chronic rhinosinusitis with nasal polyps: 300 mg every 2 weeks (Q2W) 1
- Eosinophilic esophagitis: Weight-based, ranging from 200-300 mg Q2W to 300 mg weekly (QW) for patients ≥40 kg 1
- Prurigo nodularis: 300 mg every 2 weeks after 600 mg loading dose 1
- COPD: 300 mg every 2 weeks 1
Important Clinical Considerations
Extended dosing intervals are increasingly recognized in clinical practice. Recent guidelines note that for pediatric atopic dermatitis, consideration should be given to spacing doses to every 4 weeks during childhood given the trauma of injection 2. The European Medicines Agency recommends 300 mg every 4 weeks rather than the FDA-recommended 200 mg every 2 weeks for children 30-60 kg, as efficacy data were relatively equivalent 2.
Real-world evidence demonstrates that nearly half of patients can successfully extend dosing intervals to Q3W, Q4W, or even up to Q12W without disease exacerbation 3. A systematic review confirms that extended dosing intervals (3-weekly or 4-weekly) maintain comparable efficacy to standard Q2W dosing in well-controlled patients 4.
Missed Dose Management
- Q2W dosing: If missed, administer within 7 days and resume original schedule; if >7 days, wait until next scheduled dose 1
- Q4W dosing: If missed, administer within 7 days and resume original schedule; if >7 days, administer dose and start new schedule from that date 1
- Weekly dosing: Administer as soon as possible and start new weekly schedule from that date 1
Common Pitfalls
- Don't assume all patients need Q2W dosing indefinitely—well-controlled patients may benefit from extended intervals with cost savings and reduced injection burden 3, 4
- Weight-based dosing in children is critical—using adult dosing in pediatric patients can lead to under- or over-dosing
- Loading doses are indication-specific—young children with AD (6 months-5 years) do NOT receive loading doses, unlike older age groups 1